Supply Chain Confidentiality Doesn’t Stand 'Sunshine Test', Califf Says

FDA Commissioner Makes Comments On Drug Shortages At ISPE Annual Meeting

US FDA commissioner takes aim at supplier confidentiality in remarks at ISPE annual meeting. But while greater transparency would help avert individual shortages, better economics for generic drugs are needed to solve the problem, he said.

Supply chain
urgent need seen for visibility, profitability • Source: Shutterstock

Pharmaceutical manufacturers must stop holding supply chain data confidential if the US Food and Drug Administration is to help them respond to drug shortages, which will likely continue until the generic drug sector can secure an economic footing that’s strong enough to prevent them, the agency’s commissioner, Robert Califf, told the International Society of Pharmaceutical Engineering.

“We have in front of Congress the proposals that first of all, we actually get the amounts of materials that are in the various phases of the supply chain and secondly, that we get earlier notification when demand goes up that there’s a potential for an impending shortage,” Califf said in a pre-recorded fireside chat that aired 16 October at ISPE’s annual meeting in Las Vegas. (Also see "Transparency Looms Large In US FDA’s Next-Pandemic Legislative Agenda" - Pink Sheet, 15 March, 2023

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By 

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

BGMA Becomes Medicines UK

 
• By 

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By 

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By 

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By 

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”